期刊文献+

单克隆抗体免疫亲和层析法纯化人的凝血因子Ⅸ 被引量:6

Immunoaffinity Chromatographic Purification of Human Coagulation Factor IX (FIX) by Using Conformation-specific Monoclonal Anti-body
下载PDF
导出
摘要 本文报告一种对连接钙(或镁)离子的因子Ⅸ(FⅨ)之构型具有特异性的单克隆抗体(MAb),并将其偶联Affi-Gel 15凝胶,组成亲和层析柱.将钙(或镁)离子加入含有FⅨ的原料液内,混合液流进层析柱时,唯独FⅨ被吸附,而且易被不含钙(或镁)离子的缓冲液洗脱.如洗脱液内含1 mM EDTA,则FⅨ洗脱峰十分陡峭.1 ml凝胶能吸附0.1mg的FⅨ,其吸附容量是理论容量的8%.FⅨ制品比活性为140~180活性单位/mg蛋白.在还原和非还原的SDS-PAGE电泳图谱上呈现一条谱带.此方法快速,且仅需一步即可从人血浆内提取纯化10000倍的FⅨ. An immunoaffinity method has been developed that allows for the rapid purification of human FIX. A specific monoclonal antibody for the calcium(or magnesium)-stabilized conformation of FIX was coupled to Affi-Gel 15. The immobilized anti-body was capable of binding FIX from several different sources in the presence of either Ca^(++) or Mg^(++). FIX was eluted by the buffer in the absence of Ca^(++) and Mg^(++). If there are 1mM EDTA in the elution buffer, a sharp peak of FIX will be obtained. The capacity of the column for FIX was determined to be 0.1 mg of protein per ml of resin which represents about 8% of the theoretical capacity of the column based on 2 moles of FIX binding per mole of antibody. The specific activity of the FIX product ranged between 140 and 180 units/mg and behaved as a single band on reduced and nonreduced SDS-PAGE. This immunopurification resulted in a 10,000-fold one step purification of the fully functional zymogen and has potential application for the large scale purification of FIX for specific replacement therapy in hemophilia B.
出处 《中国输血杂志》 CAS CSCD 1989年第3期111-117,共7页 Chinese Journal of Blood Transfusion
  • 相关文献

同被引文献30

  • 1王海龄,钟峻,肖小璞,李和,于劼.免疫亲和层析法纯化蛋白C[J].中国输血杂志,1993,6(1):1-5. 被引量:5
  • 2肖小璞,丁卫,李和,于,钟峻.凝血因子Ⅸ促凝活性测定方法的条件选择[J].中国输血杂志,1994,7(4):181-184. 被引量:3
  • 3-.中国生物制品规程(一部)[M].北京:中国人口出版社,1995.257.
  • 4刘世维 倪道明 等.BMM膜病毒过滤系统在血液制品中使用初步研究[J].中国输血杂志,1994,7:36-36.
  • 5Wickerhausor M,Williams C,Mercer J.Development of large-scale fractionation methods:VII prepartion of AT-Ⅲ concentrate[J].Vox Sang,1979,36(5):281-293.
  • 6Smith J K,Winkelman L,Evans DR,et al.A pasteurized AT-Ⅲ concentrate for clinical use[J].Vox Sang,1985,48(6):325-332.
  • 7Hongenbeom H,Chames R.Naturaland designer binding sitesmade by phage display technology[J].Immunol Today,2000,21:371-378.
  • 8Hoffman DL.Purification and large-scale preparation of AT-Ⅲ[J].Am J Med,1989,87(suppl 3B):23-26.
  • 9Menache D,Behre HE,Orthner CL,et al.Coagulation factorⅨ:method of preparation and assessment of potential in viso thrombogenicity in animal models[J].Blood,1984,64:1220-l227.
  • 10Jiang W,Graham B,Spiccia L,et al.Protein soleetivity with immobflized metal ion.tacn sorbents:chroma tographic studies with human sorom proteins and several other globular proteins[J].Anal Biochem,1998,255:47-78.

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部